In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
Subscribe To Our Newsletter & Stay Updated
